Lymphangioleiomyomatosis
cystic lung disease · Respiratory
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
LAM is a rare cystic lung disease affecting almost exclusively women of reproductive age, caused by proliferation of abnormal smooth-muscle-like cells with mTOR pathway activation. It presents with progressive dyspnoea, recurrent pneumothorax and chylous effusions, and can be sporadic or tuberous-sclerosis-associated.
Red flags
- Recurrent or bilateral pneumothorax
- Rapidly declining lung function
- Large renal angiomyolipoma with bleeding risk
- Chylothorax with nutritional compromise
Assessment
Differential diagnosis
- Pulmonary Langerhans cell histiocytosis
- Birt-Hogg-Dube syndrome
- Emphysema
- Lymphocytic interstitial pneumonia
- Pneumocystis (cystic pattern)
Investigations
- HRCT chest (diffuse thin-walled round cysts, uniform distribution)
- Serum VEGF-D (elevated supports diagnosis non-invasively)
- Lung function (obstructive pattern with low DLCO)
- Screen for tuberous sclerosis and renal angiomyolipomas (abdominal imaging)
- Assessment for chylous effusions and pneumothorax history
Management
- Suspect in a woman with cystic lung disease, recurrent pneumothorax or chylothorax
- Characterise the HRCT cyst pattern and assess extent
- Measure serum VEGF-D to support a non-biopsy diagnosis where cysts are characteristic
- Screen for tuberous sclerosis and abdominal angiomyolipomas
- Assess physiology with lung function and walk testing
- Start mTOR inhibitor therapy for impaired or declining lung function
- Monitor lung function trajectory to guide therapy
- Manage pneumothorax with a low threshold for definitive pleurodesis (high recurrence)
- Avoid oestrogen-containing medication and counsel on pregnancy risks
- Refer progressive disease for lung transplant assessment
Drugs & doses
Sirolimus titrated to trough 5-15 ng/mL (mTOR inhibitor) for declining lung function or chylous disease
Everolimus as an alternative mTOR inhibitor
Avoid oestrogen-containing contraceptives/HRT
Bronchodilators for the obstructive component where responsive
Disposition
Specialist / national LAM service; early pleurodesis for pneumothorax; transplant referral for advanced disease.
Complications & pitfalls
- Recurrent pneumothorax
- Chylous effusions / chylous ascites
- Progressive respiratory failure
- Renal angiomyolipoma haemorrhage
Exam pearls
- An elevated serum VEGF-D with typical cysts can confirm LAM without lung biopsy
- mTOR inhibitors (sirolimus) stabilise lung function and shrink angiomyolipomas
- Pneumothorax recurrence is very high — favour early pleurodesis
- Oestrogen may drive disease; avoid oestrogen-containing therapy
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.